<DOC>
	<DOC>NCT01626989</DOC>
	<brief_summary>Comparing two BiPAP autoSV devices in participants with complex sleep apnea and determining if the new device will treat those participants no worse than when compared to its predecessor device.</brief_summary>
	<brief_title>Evaluation of the Philips Respironics BiPAP autoSV Devices in Subjects With Sleep Disorders</brief_title>
	<detailed_description>The use of the BiPAP autoSV4 device in participants with Complex Sleep Apnea Syndrome will treat those participants no worse than when compared to its predecessor device, the BiPAP autoSV Advanced™, with respect to: • Apnea-Hypopnea Index (AHI)</detailed_description>
	<mesh_term>Sleep Apnea, Central</mesh_term>
	<criteria>Age 2180 Ability to provide consent Documentation of medical stability by investigator Subjects who currently have been on PAP therapy for ≥ 4 weeks and who previously had a CPAP titration with CAI ≥ 5. OR Subjects who currently have been on PAP therapy for ≥ 4 weeks and who had a diagnostic study done, with a CAI ≥ 5, and were prescribed PAP therapy without a CPAP titration. Agreement to undergo a fullnight, inlab research CPAP Titration Agreement to undergo two fullnight, inlab therapy research PSG on BiPAP autoSV devices Major medical or psychiatric condition that would interfere with the demands of the study, adherence to positive airway pressure, or the ability to complete the study. For example, unstable congestive heart failure, chronic lung disease, neuromuscular disease, daytime hypercapnia, cancer, or renal failure. Systolic blood pressure &lt; 80 mm Hg at Baseline Visit. Participants in whom PAP therapy is otherwise medically contraindicated. Participants who are unwilling to wear CPAP Currently prescribed oxygen therapy (as needed, nocturnal, or continuous Participants with previously diagnosed respiratory failure or respiratory insufficiency and who are known to have chronically elevated arterial carbon dioxide levels while awake (PaCO2 ≥ 45mmHg). Participants who have had surgery of the upper airway, nose, sinus, or middle ear within the previous 90 days. Participants with untreated, nonOSA/CSA sleep disorders, including but not limited to; insomnia, periodic limb movement syndrome, or restless legs syndrome (PLM Arousal Index &gt; 15).</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>